#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary amyloidosis Henoch-Schonlein purpura Progressive supranuclear palsy Pituitary-dependent Cushing's syndrome Philadelphia positive chronic myeloid leukaemia Facioscapulohumeral muscular dystrophy Malformation venous Bronchiolitis Retinal dystrophy Acute myeloid leukaemia refractory Pyruvate dehydrogenase complex deficiency Fibrosarcoma metastatic Fallopian tube cancer B-cell lymphoma recurrent Hypomagnesaemia More trials…

    Learn about Rare Diseases

    Hepatic angiosarcoma – Life with Disease Proteus syndrome – Diagnostics Waldenstrom’s macroglobulinaemia – Life with Disease Sjogren’s syndrome – Treatment Niemann-Pick disease – Basic Information Hairy cell leukaemia recurrent – Trials in Disease Primary mediastinal large B-cell lymphoma – Basic Information Kearns-Sayre syndrome – Basic Information Leukoencephalopathy – Life with Disease Alexander disease – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Baclofen ALLO-QUADCAR01-T GOVORESTAT Gandotinib BNT327 Montelukast Siltuximab Mps-214 Dimethyl Fumarate Cemiplimab Faricimab Vo659 Nirogacestat Hydrobromide Vibegron Mifepristone Tx200-Tr101 XELAFASLATIDE Magnesium Chloride Aprepitant LUNRESERTIB More therapies…

    Learn about Your Condition

    White matter lesion Mast cell activation syndrome Follicular lymphoma HER2 negative breast cancer Obliterative bronchiolitis Ocular myasthenia Hypersensitivity Inborn error of metabolism Thrombosis Hyperglycaemia Thyroidectomy Lichen sclerosus Left ventricular dysfunction Cardiac disorder Spinal cord injury More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

B-cell small lymphocytic lymphoma

  • A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Zanubrutinib
    • Acalabrutinib
    Czechia France Germany Italy The Netherlands Poland +3

  • A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • BGB-16673
    • Pirtobrutinib
    Austria Belgium France Germany Italy The Netherlands +4

  • A Study Comparing DZD8586 to Other Treatments for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL
    • Idelalisib
    • Bendamustine Hydrochloride
    Italy Poland

  • Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Mitoxantrone Hydrochloride
    • Vinblastine Sulfate
    • Cladribine
    France Germany Poland

  • Study of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment

    Recruiting

    2 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • B-cell small lymphocytic lymphoma
    France Hungary Italy Poland

  • Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • BGB-16673
    • Idelalisib
    • Bendamustine Hydrochloride
    Czechia Germany Italy The Netherlands Poland
1 2 3 … 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!